- Home
- GGAL vs STVN Comparison
GGAL vs STVN Comparison
Compare GGAL & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | STVN |
|---|---|---|
| Founded | 1905 | 1949 |
| Country | Argentina | Italy |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Containers/Packaging |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.7B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GGAL | STVN |
|---|---|---|
| Price | $41.50 | $21.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $69.00 | $25.67 |
| AVG Volume (30 Days) | ★ 685.9K | 351.4K |
| Earning Date | 03-07-2023 | 05-07-2026 |
| Dividend Yield | ★ 3.70% | 0.39% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.29 | $9.67 |
| Revenue Next Year | $22.88 | $9.99 |
| P/E Ratio | ★ $13.36 | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.06 | $12.89 |
| 52 Week High | $62.11 | $28.00 |
Technical Indicators
Market Signals| Indicator | GGAL | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 52.47 |
| Support Level | $40.08 | $20.03 |
| Resistance Level | $45.33 | $22.00 |
| Average True Range (ATR) | 1.29 | 0.85 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 1.25 | 49.94 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About STVN Stevanato Group S.p.A.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.